# Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

Study · id `cardio:ct-nct03271879` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03271879](<https://clinicaltrials.gov/study/NCT03271879>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03271879

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

## Technical summary

Registry record NCT03271879. Randomized; double masking; primary purpose treatment. Start 2018-02-15 (anticipated); primary completion 2019-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 128 participants (planned count; ClinicalTrials.gov record NCT03271879, source copy `cardio:ctgov-nct03271879-2018-01-25`, retrieved 2026-10-26)
- Planned start: 2018-02-15 (anticipated) (ClinicalTrials.gov record NCT03271879, source copy `cardio:ctgov-nct03271879-2018-01-25`, retrieved 2026-10-26)
- Primary completion: 2019-09-01 (anticipated) (ClinicalTrials.gov record NCT03271879, source copy `cardio:ctgov-nct03271879-2018-01-25`, retrieved 2026-10-26)
- Completion: 2020-06-01 (anticipated) (ClinicalTrials.gov record NCT03271879, source copy `cardio:ctgov-nct03271879-2018-01-25`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03271879-2018-01-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
- Acronym: ERA-HF
- Condition: Heart Failure
- Condition: Diabetes Mellitus
- Condition: Arrythmia
- Intervention (Drug): Empagliflozin at a dose of 10 mg/day
- Lead sponsor: Rambam Health Care Campus
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Rambam Health Care Campus (`cardio:org-rambam-health-care-campus`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 327c6a7c38c931385a4a0a1440ae3e1c68121866dad53e1c0278abb60484e41c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
